Educational Areas/Call for Grants
Use a maximum of two downloads here
| Areas of Educational Interest | Available Funding |
Call for Grants | |
|---|---|---|---|
| CARDIOVASCULAR | |||
| Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) |  |
||
| Hypertension | |
||
| INFECTIONS & VACCINES | |||
| Infections & Vaccines – Other (Non-US Only) | |
||
| Influenza (Non-US Only) | |
||
| Respiratory Syncytial Virus (RSV) - (Non-US Only) |  |
||
| SARS-CoV-2 Monoclonal Antibodies (Non-US Only) | |
||
| NEPHROLOGY | |||
| Hyperkalemia | |
||
| NEUROLOGY | |||
| Transthyretin Amyloidosis Polyneuropathy (ATTR-PN) | |
||
| ONCOLOGY - BLADDER CANCER | |||
| HER2 Expression – Bladder Cancer | |
||
| Immuno-Oncology - Bladder Cancer | |
||
| Immuno-Oncology - NMIBC (Non-Muscle Invasive Bladder Cancer) | |
||
| Immuno-Oncology - MIBC (Muscle Invasive Bladder Cancer) | |
||
| Immuno-Oncology - mUC (Metastatice Urothelial Cancer) | |
||
| ONCOLOGY - BREAST CANCER | |||
| Breast Cancer - BRCAm Early and/or Late | |
||
| Breast Cancer - Emerging biomarkers | |
||
| Breast Cancer - Endocrine therapy resistance | |
||
| Breast Cancer - HER2 expression | |
||
| Breast Cancer – HER2+ | |
||
| Breast Cancer – HER2-low | |
||
| Breast Cancer – ER+ Metastatic | |
||
| Breast Cancer - PARP Inhibition | |
||
| Breast Cancer - TNBC (triple negative breast cancer) | |
||
| Breast Cancer – TROP2 Expression | |
||
| ONCOLOGY - CERVICAL CANCER | |||
| Cervical Cancer – HER2 Expression | |
||
| ONCOLOGY - ENDOMETRIAL CANCER | |||
| Immuno-Oncology - Endometrial Cancer | |
||
| Endometrial Cancer – HER2 Expression | |
||
| ONCOLOGY - ESOPHAGEAL CANCER | |||
| Locally Advanced Esophageal Squamous Cell Carcinoma | |
||
| ONCOLOGY - GASTRIC CANCER | |||
| Gastric Cancer - HER2+ | |
||
| Gastric Cancer - HER2 Expression – Colorectal Cancer (CRC) | |
||
| Immuno-Oncology – Gastric Esophageal Junction Cancer (GEJC) | |
||
| Immuno-Oncology – Gastric Cancer (GC) | |
||
| ONCOLOGY - HEMATOLOGY | |||
| Hematology - ALL | |
||
| Hematology - CLL (Chronic Lymphocytic Leukemia) | |
||
| Hematology – DLBCL | |
||
| Hematology – FL | |
||
| Hematology - MCL (Mantle Cell Lymphoma) | |
||
| Hematology – Multiple Myeloma | |
||
| ONCOLOGY – HEPATOBILIARY CANCERS | |||
| Bispecifics - Hepatobiliary Cancers (HCC and BTC) | |
||
| ONCOOGY - LIVER CANCER / BILIARY TRACT CANCER | |||
| HER2 Expression – Biliary Tract Cancer (BTC) | |
||
| Immuno-Oncology - Biliary Tract Cancer (BTC) | |
||
| Immuno-Oncology – eHCC (early Hepatocellular Carcinoma) |  |
||
| Immuno-Oncology - HCC (Hepatocellular Carcinoma) | |
||
| Immuno-Oncology - iHCC (intermediate stage Hepatocellular Carcinoma) | |
||
Immuno-Oncology - uHCC (unresectable Hepatocellular Carcinoma) |
|
||
| ONCOLOGY - LUNG CANCER | |||
| Lung Cancer - EGFR+ NSCLC | |
||
| Lung Cancer – HER2 Non-Small Cell Lung Cancer | |
||
| Lung Cancer - Immuno-Oncology - Non-Small Cell Lung Cancer (NSCLC) | |
|
|
| Lung Cancer - Immuno-Oncology Small Cell Lung Cancer (SCLC) | |
||
| Lung Cancer - TROP-2 Expression Non-Small Cell Lung Cancer (NSCLC) | |
||
| Lung Cancer - Mesothelioma | |
||
| ONCOLOGY - OVARIAN CANCER | |||
| Ovarian Cancer - BRCA | |
||
| Ovarian Cancer - DNA Damage Response | |
||
| Ovarian Cancer – HER2 Expression | |
||
| Ovarian Cancer - Non-BRCA | |
||
| Ovarian Cancer - PARP Inhibition | |
||
| ONCOLOGY - PANCREATIC CANCER | |||
| Pancreatic Cancer - BRCA | |
||
| Pancreatic Cancer - DNA Damage Response | |
||
| ONCOLOGY – PROSTATE CANCER | |||
| Prostate Cancer – Actinium 225 | |
||
| Prostate Cancer – AKT Inhibition | |
||
| Prostate Cancer – De novo mHSPC | |
||
| Prostate Cancer - DNA Damage Response (mCRPC) | |
||
| Prostate Cancer - DNA Damage Response (mHSPC) | |
||
| Prostate Cancer - Homologous Recombination Repair (mCRPC) | |
||
| Prostate Cancer - Homologous Recombination Repair (mHSPC) | |
||
| Prostate Cancer - PARP inhibition (mCRPC) | |
||
| Prostate Cancer - PARP inhibition (mHSPC) | |
||
| Prostate Cancer – PARP1 Selective | |
||
| Prostate Cancer – Prostate Specific Membrane Antigen (PSMA) | |
||
| Prostate Cancer – PTEN / Testing | |
||
| Prostate Cancer – Radioconjugates | |
||
| RESPIRATORY | |||
| Asthma - (limited budget; email concept to grants@astrazeneca.com) | |
||
| Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) - (For those applications not being submitted in response to a CGA, email concept to grants@astrazeneca.com) | |
||
| COPD - (email concept to grants@astrazeneca.com) | |
||
| Eosinophilic Esophagitis - (email concept to grants@astrazeneca.com) | |
||
| Eosinophilic Granulomatosis with Polyangiitis (EGPA) - (limited budget; email concept to grants@astrazeneca.com) | |
||
| Hypereosinophilic Syndromes (HES) - (limited budget; email educational concept to grants@astrazeneca.com) | |
||
| Severe Asthma - (Quality Improvement Education requests only; email educational concept to grants@astrazeneca.com) | |
||
| Severe Viral Lower Respiratory Tract Disease (severe viral LRTD) - (limited budget available; email educational concept to grants@astrazeneca.com) | |
||
| RHEUMATOLOGY / IMMUNOLOGY / AUTOIMMUNE | |||
| Systemic Lupus Erythematosus (SLE) - (limited budget available; email educational concept to grants@astrazeneca.com) | |
||
| Cutaneous Lupus Erythematosus (Non-US Only) | |
||
| Lupus Nephritis (Non-US Only) | |
||
| Myositis (Non-US Only) | |
||
| Systemic Sclerosis (Non-US Only) | |
||
| R & D Discovery | |||
| Scientific or educational activities designed to educate research scientists, principal researchers, drug development professionals, academics, pre-doctoral students, doctoral students and fellows. These programs must be educational and non-promotional in nature and planned, designed and implemented in accordance with the U.S. Food and Drug Administration's Guidance on Industry-Supported Scientific and Educational Activities. | |
||